ArticleCirculation2011
Transcriptomic biomarkers for the accurate diagnosis of myocarditis.
Article in Circulation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 95 citations in OpenAlex.
- Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.Journal of cardiovascular translational research · 2014Trial
- Identification and clinical evaluation of diagnostic biomarkers for ischemic cardiomyopathy based on machine learning and transcriptomics.Frontiers in cardiovascular medicine · 2026Article
- Review
- An Exercise Immune Fitness Test to Unravel Disease Mechanisms-A Proof-of-Concept Heart Failure Study.Journal of clinical medicine · 2024Article
- Sex and Age Characteristics in Acute or Chronic Myocarditis A Descriptive, Multicenter Cohort Study.JACC. Advances · 2024Article
- Myocarditis in Athletes: Risk Factors and Relationship with Strenuous Exercise.Sports medicine (Auckland, N.Z.) · 2024Review
- Mesenchymal STRO-1/STRO-3Future cardiology · 2023Review
- COVID-19, Myocarditis and Pericarditis.Circulation research · 2023Review
- From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children.International journal of molecular sciences · 2023Review
- Severe heart failure in the setting of inflammatory cardiomyopathy with likely pathogenic titin variant.International journal of cardiology. Heart & vasculature · 2022Article
- Influence of Disease Severity and Gender on HLA-C Methylation in COVID-19 Patients.Iranian journal of science and technology. Transaction A, Science · 2022Article
- Role of Toll-Like Receptors and Th Responses in Viral Myocarditis.Frontiers in immunology · 2022Review
- Human disease biomarker panels through systems biology.Biophysical reviews · 2021Review
- Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01.EClinicalMedicine · 2021Article
- Predicting tissue-specific gene expression from whole blood transcriptome.Science advances · 2021Article
- Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.Nature reviews. Cardiology · 2021Review
- Expression Profiles and Potential Functions of Long Non-Coding RNAs in the Heart of Mice With Coxsackie B3 Virus-Induced Myocarditis.Frontiers in cellular and infection microbiology · 2021Article
- Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.International journal of molecular sciences · 2020Review
- Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and Treatment.Current cardiology reports · 2020Review
- Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.Cardiac failure review · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLymphocytic myocarditis is a clinically important condition that is difficult to diagnose and distinguish. We hypothesized that the transcriptome obtained from an endomyocardial biopsy would yield clinically relevant and accurate molecular signatures. METHODS AND
resultsMicroarray analysis was performed on samples from patients with histologically proven lymphocytic myocarditis (n=16) and idiopathic dilated cardiomyopathy (n=32) to develop accurate diagnostic transcriptome-based biomarkers using multiple classification algorithms. We identified 9878 differentially expressed genes in lymphocytic myocarditis versus idiopathic dilated cardiomyopathy (fold change >1.2; false discovery rate <5%) from which a transcriptome-based biomarker containing 62 genes was identified that distinguished myocarditis with 100% sensitivity (95% confidence interval, 46 to 100) and 100% specificity (95% confidence interval, 66 to 100) and was generalizable to a broad range of secondary cardiomyopathies associated with inflammation (n=27), ischemic cardiomyopathy (n=8), and the normal heart (n=11). Multiple classification algorithms and quantitative real-time reverse-transcription polymerase chain reaction analysis further reduced this subset to a highly robust molecular signature of 13 genes, which still performed with 100% accuracy.
conclusionsTogether, these findings demonstrate that transcriptomic biomarkers from a single endomyocardial biopsy can improve the clinical detection of patients with inflammatory diseases of the heart. This approach advances the clinical management and treatment of cardiac disorders with highly variable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.